Benjamin Creelan
Overview
Explore the profile of Benjamin Creelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
1408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turcotte S, Donia M, Gastman B, Besser M, Brown R, Coukos G, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39837618
In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is...
2.
Alban T, Riaz N, Parthasarathy P, Makarov V, Kendall S, Yoo S, et al.
Nat Med
. 2024 Sep;
30(11):3209-3222.
PMID: 39349627
Neoantigen immunoediting drives immune checkpoint blockade efficacy, yet the molecular features of neoantigens and how neoantigen immunogenicity shapes treatment response remain poorly understood. To address these questions, 80 patients with...
3.
Schrock A, Zhu V, Hsieh W, Madison R, Creelan B, Silberberg J, et al.
J Thorac Oncol
. 2018 Jun;
13(9):1312-1323.
PMID: 29883838
Introduction: We analyzed a large set of EGFR-mutated (EGFR+) NSCLC to identify and characterize cases with co-occurring kinase fusions as potential resistance mechanisms to EGFR tyrosine kinase inhibitors (TKIs). Methods:...
4.
Carbone D, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al.
N Engl J Med
. 2017 Jun;
376(25):2415-2426.
PMID: 28636851
Background: Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab...
5.
Creelan B, Ferber A
Am J Ther
. 2008 Jan;
15(1):82-4.
PMID: 18223357
Alemtuzumab is a humanized monoclonal antibody primarily used in refractory chronic lymphocytic leukemia. Although bronchospasm and infectious pneumonia are not uncommon adverse effects of therapy, alemtuzumab-associated interstitial pneumonitis causing acute...